Novel Class of Antibody-Drug Conjugates (ADC) to address Resistant Solid Malignancies

RHEADC is preclinical-stage private biotech company dedicated to enhancing treatment outcomes for patients with solid malignancies.
The company leads the way in creating an innovative category of antibody-drug-conjugates (ADC) designed to specifically target the intrinsic resistance mechanism of solid cancers that often lead to treatment failures.
RHEADC’s first ADC specifically targets ABCB5, a novel and promising tumor antigen that specifically marks resilient tumor cells an has unique biologic features making it an attractive ADC target.

RHEADC develops the first ADC that specifically targets resilient cancer cells.
ABCB5 is overexpressed in a range of solid cancers, including melanoma, liver, colorectal, glioblastoma, and head and neck cancers.
Early preclinical human xenograft studies have demonstrated that our pilot ABCB5-ADC significantly suppresses tumor growth and extends survival.

(c) 2024 – RHEADC – Leuven, Belgium
info@rheadc.com